GLP-1 Agonists: A New Option for Hospital Blood Sugar Control?

Type 2 diabetes mellitus is a chronic condition often managed with various therapies. In outpatient settings, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant benefits for long-term glycemic control and reducing complications associated with chronic inflammation. However, the role of these agents in managing dysglycemia (abnormal blood sugar levels) in acutely ill, hospitalized patients has been less explored, representing a critical knowledge gap.

The review confirmed that GLP-1 RAs are highly effective for long-term glycemic control in outpatient settings for type 2 diabetes, also reducing complications linked to chronic inflammation. Preclinical studies consistently indicate that GLP-1 RAs positively influence the inflammatory response across diverse models of acute inflammation. Emerging clinical data strongly suggest that GLP-1 RAs could serve as a viable alternative or valuable complement to traditional insulin therapy for managing blood sugar levels in hospitalized patients. This potential extends beyond simple glucose lowering, encompassing a broader modulation of acute inflammatory processes, which is particularly relevant in critically ill populations. While specific quantitative data (e.g., percent reduction in blood glucose or p-values) from this review are not provided, the collective evidence points to significant therapeutic promise.